X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia ATL5
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia ATL5
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: University of Nebraska Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Nantheia ATL5, an oral therapy containing 100mg of cannabidiol per capsule, features proprietary delivery technology (Liquid Structure) touted as enhancing the effectiveness and stability of cannabidiol.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NYU Langone Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
Pre-clinical and initial clinical studies show that ANANDA's Liquid Structure™ delivery technology enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 (cannabidiol) is an oral product with 100mg cannabidiol per softgel capsule.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia ATL5
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
Nantheia ATL5 is an investigational drug that uses cannabidiol in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Nebraska Medical Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Nantheia™ A1002N5S is an investigational drug that uses CBD in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology enhances the effectiveness and stability of CBD.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NYU Grossman School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for opioid use disorder. Nantheia™ ATL5 is an oral softgel capsule and is investigational drug utilizing Liquid Structure™ technology.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lyotropic Delivery Systems
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
